Invesco provides investment management services to retail (72% of managed assets) and institutional (28%) clients... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PML | 6.59 | N/A | N/A |
| PIMCO Municipal Income FUND II | |||
| XSLV | 49.41 | -0.38 | -0.77% |
| Invesco S&P SmallCap Low Volatility ETF (XSLV) | |||
| FARX | 28.69 | -0.25 | -0.85% |
| Frontier Asset Absolute Return ETF | |||
| TEND | 26.00 | -0.75 | -2.82% |
| iShares Large Cap 10% Target Buffer Dec ETF (TEND) | |||
| IWF | 101.72 | -6.52 | -6.02% |
| iShares Russell 1000 Growth ETF (IWF) | |||
A.I.dvisor indicates that over the last year, IVZ has been closely correlated with BLK. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if IVZ jumps, then BLK could also see price increases.
a provider of investment management services
Industry InvestmentManagers
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IVZ declined for three days, in 201 of 287 cases, the price declined further within the following month. The odds of a continued downward trend are 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 56 cases where IVZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVZ as a result. In 58 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for IVZ turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 31 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
The Aroon Indicator for IVZ entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IVZ's RSI Indicator exited the oversold zone, 20 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVZ advanced for three days, in 227 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
IVZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. IVZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.200) is normal, around the industry mean (2.423). IVZ has a moderately low P/E Ratio (-40.418) as compared to the industry average of (8.341). Projected Growth (PEG Ratio) (0.901) is also within normal values, averaging (1.318). Dividend Yield (0.032) settles around the average of (0.274) among similar stocks. P/S Ratio (1.981) is also within normal values, averaging (15.906).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.